Launching Clinical Trials In India? Beware Of Long Delays And New Mandates
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Inordinate delays in the approval process for clinical trials may be dissuading sponsors and CROs from considering India as part of their upcoming global programs
You may also be interested in...
Sneak Preview: R&D Investments Must Focus On India’s Competitive Advantages
India has unique capabilities for genomic databases, translational research and nanotechnology, which should spur research on cancer leads, according to a BCG report to be released May 11.
Sneak Preview: R&D Investments Must Focus On India’s Competitive Advantages
India has unique capabilities for genomic databases, translational research and nanotechnology, which should spur research on cancer leads, according to a BCG report to be released May 11.
Indian Government In Dilemma As DCGI's Competence Is Questioned Amid Mounting Criticism
MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh